Wedbush Lowers Earnings Estimates for Larimar Therapeutics

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Investment analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report released on Monday, March 24th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.39) per share for the quarter, down from their previous forecast of ($0.25). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.52) EPS, FY2026 earnings at ($1.73) EPS and FY2027 earnings at ($1.17) EPS.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright boosted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday. Finally, Robert W. Baird dropped their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $20.22.

Larimar Therapeutics Trading Down 2.6 %

Shares of LRMR opened at $2.25 on Wednesday. The stock has a market capitalization of $143.57 million, a price-to-earnings ratio of -1.96 and a beta of 0.99. Larimar Therapeutics has a 12 month low of $2.19 and a 12 month high of $11.20. The firm has a fifty day simple moving average of $3.11 and a 200 day simple moving average of $5.18.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

Institutional Investors Weigh In On Larimar Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its position in shares of Larimar Therapeutics by 10.3% in the fourth quarter. Wellington Management Group LLP now owns 116,067 shares of the company’s stock valued at $449,000 after purchasing an additional 10,821 shares during the period. Velan Capital Investment Management LP acquired a new position in Larimar Therapeutics in the 4th quarter valued at about $70,000. Sphera Funds Management LTD. raised its holdings in Larimar Therapeutics by 9.9% in the 4th quarter. Sphera Funds Management LTD. now owns 455,604 shares of the company’s stock valued at $1,763,000 after acquiring an additional 41,126 shares during the period. ProShare Advisors LLC acquired a new stake in Larimar Therapeutics during the fourth quarter worth approximately $58,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Larimar Therapeutics by 15.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after acquiring an additional 876,431 shares during the period. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.